Prolaio
We're Hiring!
Prolaio Company Growth, Stability & Outlook
What People Are Saying About Prolaio
-
Strong Hiring & Retention: Headcount is reported to have expanded by 32 in 2025, and current listings show multiple open roles across engineering, data, security, operations, and customer success. LinkedIn also shows roughly 85 employees, reinforcing sustained organizational growth.
-
Product Line Growth: Regulatory and product momentum includes FDA clearance of the eVO2peak Module in December 2025 and a portfolio the company describes as 12 cardiovascular digital biomarkers (8 FDA-cleared, 4 clinically validated). This indicates an expanding set of regulated and validated offerings on its platform.
-
Strategic Partnerships: Integration into Kardigan following the 2025 acquisition connects the platform to an active cardiovascular drug-development pipeline and clinical programs. SEC disclosures outline Prolaio-related patient and revenue milestones and describe deployment in Kardigan’s trials.
